Last reviewed · How we verify

NCT03751969

A Study Evaluating the Mass Balance of Micro-dose[14C]HSK3486 Emulsion Injection in Healthy Adults

Withdrawn Phase 1 Last updated 2 June 2022
What this trial tests

Phase 1 trial testing HSK3486 in Anesthesia. Withdrawn.

Timeline
30 March 2020
Primary endpoint
1 November 2020
1 December 2020

Quick facts

Lead sponsorSichuan Haisco Pharmaceutical Group Co., Ltd
PhasePhase 1
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Start date30 March 2020
Primary completion1 November 2020
Estimated completion1 December 2020

Drugs / interventions tested

Conditions studied

Sponsor

Sichuan Haisco Pharmaceutical Group Co., Ltd — full company profile →

Who can join

Adults 18 to 49, male only, with Anesthesia or Sedation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is designed to evaluate the mass balance in healthy Chinese male subjects after receiving a single dose of intravenous \[14C\]HSK3486, so as to assess the overall pharmacokinetics and safety of HSK3486 in humans and provide a reference for reasonable use of this drug.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of HSK3486

Trials testing the same drug.

Other recruiting trials for Anesthesia

Currently open trials in the same condition.

Other Sichuan Haisco Pharmaceutical Group Co., Ltd trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03751969.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing